Sensible Biotechnologies, Inc., an mRNA platform company, has announced a $4.2mn pre-seed round to accelerate the development of its cell-based platform for cost-efficient manufacturing of high-quality mRNA.
mRNA is typically made via cell-free methods. By leveraging processes in engineered living cells, we produce high-quality mRNA in a cost-efficient and scalable fashion.